Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, ...

Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Committee ...